Skip to content

Proven Outcomes. Real Impact.

Measured. Validated. Defensable.

Review independently validated findings, peer-reviewed research, and measured client results. Every result includes the population, timeframe, methodology, and source needed to evaluate it.

uspm-about-slider-10-team-faces
Measured. Validated. Sustained.

41%

ER Visits & Hospital Reduction

Reduction in combined hospital admissions and ER visits per 1,000 members by Year 4 across multiple employer populations representing 33,459 members

23% → 16%

High-Risk Diabetes Reduction

Across 7,804 participants at 15 employers, 23% reduced their health risks over two years, compared with 16% expected under the Edington Natural Flow model (P

$5.6M

Medical & Pharmacy Claims Reduction

Cumulative medical and pharmacy claims savings after program costs over three years among 299 participants in a diabetes management program

* Examples are based on de-identified analyses and outcomes from actual USPM client populations. Individual results may vary.
Independently Validated by the Validation Institute | USPM | United States Preventive Medicine

Independently Validated

uspm-logo-validation-institute-partner

USPM's outcomes and measurement methodologies have been independently validated by the Validation Institute, supporting the rigor and consistency of how results are measured, evaluated, and reported.

Results Across Populations

Diabetes Population
Weight Management
Population Health
299 Individuals
22% Weight Loss
40% Reduction
89% → 4% High-Risk Diabetes
Sustained Engagement
43% → 29% Condition Burden
$5.6M Claims Reduction
200+ Weekly Activity Minutes
ER & Hospital Utilization
Data Reveals Opportunity

01

Data Reveals Opportunity

Four Years of Lower Hospital and ER Use

Case Study

Primary Result

41% reduction in combined hospital admissions and ER visits per 1,000 members by Year 4.

The analysis evaluated utilization across asthma, cardiac and hypertension events, congestive heart failure, COPD and respiratory conditions, and diabetes. Results were evaluated against Disease Management Purchasing Consortium and Healthcare Cost and Utilization Project national benchmarks.

Multiple employer populations

N=33,459 | Four-year analysis

Source

uspm-logo-independently-validate-performance-badge
Case Study 1 Graphic | Bar Chart showing USPM impact on Annual Reduction in Combined Hospital Admissions and ER Visits
previous arrow
next arrow
PlayPause

A separate case study analyzing the impact of our diabetes (type I & II) management program found even more impactful results…

* Multiyear sustained reductions in hospitalizations and ER visits (per 1,000 members)

80% reduction in Hospital Inpatient Days

Nearly 50% reduction in total medical/pharmaceutical costs

Average annual savings per participant of $6,312

Total client savings of $5.6 million after factoring in program costs

Diabetes Disease Management
Case Study

uspm-success-stories-img-diabetes-results

Average savings after factoring in program costs of $6,312 per program participant (diabetes) an average savings of 42% from pre-program to post program results over the three years.
After three years of USPM Diabetes Managment program.

Saving reduced the client’s diabetes related spending by $5.6 million over 3 years.

Testimonials

Healthy living made fun.

Peer Reviewed
Medical Journal Findings

uspm-logo-media-partner-joem

A separate study published in the Journal of Occupational and Environmental Medicine showed:

USPM’s root caused based approach significantly reduced health risks across the covered population:

  • 41% of high risk participants were no longer high risk after 2 years*
  • 52% of high risk participants were no longer high risk after 5 years*

Program participants also realized clinically significant movement in key biomarkers

21%

BMI

20%

Glucose

20%

Cholesterol

32%

HDL Values

* Multiyear sustained reductions in hospitalizations and ER visits (per 1,000 members)
The Price We Pay, Marty Makary, MD & FDA Commissioner
"USPM is a shining example of what's possible when companies do wellness right."
Marty Makary, MD & FDA Commissioner
Marty Makary
MD & FDA Commissioner

*Intel-GE Care Innovations Validation Institute
*Lifestyle Medicine, Third Edition, edited by James M. Rippe, MD. Section Figure 105.4, “USPM Total Hospital Admits and ER Visits across Conditions vs. *DMPC and HCUP National Averages (per 1000 Members).,” p. 12 of 15
*¹ Lifestyle Medicine, Third Edition, edited by James M. Rippe, MD. Section 105.6.2, “Intel-GE Validation Institute Recognition of U.S. Preventive Medicine,” p. 11 of 15
*Lifestyle Medicine, Third Edition, edited by James M. Rippe, MD. Section 105.6.1 “Client Case Study Results,” p. 10 of 15
*Loeppke, R; Edington, D; Bender, J; Reynolds, A. “The Association of Technology in a Workplace Wellness Program with Health Risk Factor Reduction” Journal of Occupational and Environmental Medicine: March 2013; Volume 55, Number 3: pp 259–264
*Loeppke, R; “The Why, How and What in Leveraging the Value of Health.” in Rippe, James, M. (Ed.) Lifestyle Medicine, Third Edition. CRC Press: Boca Raton, Florida: May 2019.
*Loeppke, R; Edington, D; Bender, J; Reynolds, A. “The Association of Technology in a Workplace Wellness Program with Health Risk Factor Reduction” Journal of Occupational and Environmental Medicine: March 2013; Volume 55, Number 3: pp 259–264

See What USPM Can Deliver for Your Population

Reduce cost. Improve outcomes. Engage your population with a clinically driven model built to deliver measurable performance.